ORCHPHARMA Orchid Pharma Q2 FY25 results (Jul–Sep 2024) and concall
Orchid Pharma reported strong half-year performance with sales growing 22% and EBITDA up 43.7% YoY, driven by business development and customer base regaining. The company successfully launched its key drug ORBLICEF in India and commenced EU sales for Enmetazobactam. Key projects like capacity expansion and 7ACA are progressing, though regulatory observations for Ceftazidime/Avibactam and delays in ORBLICEF's US/China commercialization remain areas of focus.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 223 |
| EBITDA | 30 |
| Net profit | 27 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
